IFNA2 and cardiovascular disorder: Intriguingly, silencing miR-216a-3p could alleviate inflammation in cardiovascular diseases with T2DM by targeting IFN-α2 and through the inactivation of the TLR pathway, which may provide a novel target for the treatment of T2DM.